Clinical Trials Study
Copyright ©The Author(s) 2024.
World J Gastroenterol. Mar 7, 2024; 30(9): 1108-1120
Published online Mar 7, 2024. doi: 10.3748/wjg.v30.i9.1108
Table 5 Treatment effectiveness with patients stratified according to Helicobacter pylori status, n (%)
MPA effectiveness, n = 3563
PPI effectiveness, n = 3563
MPA + PPI effectiveness, n = 3563
MPA + PPI + PD effectiveness, n = 3563
P value
Hp (+)
Hp (-)
Hp (+)
Hp (-)
Hp (+)
Hp (-)
Hp (+)
Hp (-)
Epigastric pain26 (47.3)148 (56.5)27 (51.9)86 (42.8)91 (67.9)527 (66.5)10 (47.6)161 (70.3)0
Abdominal distension24 (43.6)143 (54.6)29 (55.8)99 (49.3)74 (55.2)424 (53.5)15 (71.4)141 (61.6)0.092
Postprandial fullness21 (38.2)135 (51.5)22 (42.3)63 (31.3)55 (41.0)323 (40.7)8 (38.1)118 (51.5)0
Early satiety19 (34.5)102 (38.9)15 (28.8)31 (15.4)36 (26.9)230 (29.0)6 (28.6)83 (36.2)0
Acid regurgitation29 (52.7)102 (38.9)25 (48.1)61 (30.3)38 (28.4)340 (42.9)10 (47.6)127 (55.5)0
Nausea24 (43.6)88 (33.6)15 (28.8)36 (17.9)28 (20.9)190 (24.0)2 (9.5)73 (31.9)0
Belch28 (50.9)115 (43.9)21 (40.4)50 (24.9)37 (27.6)259 (32.7)4 (19.0)118 (51.5)0
Vomiting16 (29.1)54 (20.6)11 (21.2)18 (9.0)17 (12.7)103 (13.0)1 (4.8)38 (16.6)0
Others21 (38.2)135 (51.5)22 (42.3)63 (31.3)55 (41.0)323 (40.7)8 (38.1)118 (51.5)0
MPA: Mucosal protective agent; PPI: Proton pump inhibitor; PD: Prokinetic drug; Hp: Helicobacter pylori.
  • Citation: Yang YY, Li KM, Xu GF, Wang CD, Xiong H, Wang XZ, Wang CH, Zhang BY, Jiang HX, Sun J, Xu Y, Zhang LJ, Zheng HX, Xing XB, Wang LJ, Zuo XL, Ding SG, Lin R, Chen CX, Wang XW, Li JN. Clinical manifestation, lifestyle, and treatment patterns of chronic erosive gastritis: A multicenter real-world study in China. World J Gastroenterol 2024; 30(9): 1108-1120
  • URL: https://www.wjgnet.com/1007-9327/full/v30/i9/1108.htm
  • DOI: https://dx.doi.org/10.3748/wjg.v30.i9.1108